Skip to main content

Table 2 HAE-specific medications used during study period (2006–2014) in 631 patients with HAE in the USa

From: Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States

HAE Medications N (%) of Patients (N = 631)
Icatibant and/or ecallantide only 197 (31.2)
Any use C1-INH(IV) 434 (68.8)
 C1-INH(IV)/Cinrzye 110 (17.4)
 C1-INH(IV)/Cinryze + icatibant/ecallantide 97 (15.4)
 C1-INH(IV)/Berinert 87 (13.8)
 C1-INH(IV)/Berinert + icatibant/ecallantide 53 (8.4)
 C1-INH(IV)/Cinryze + C1-INH(IV)/Berinert + icatibant/ ecallantide 49 (7.8)
 C1-INH(IV)/Cinryze + C1-INH(IV)/Berinert 38 (6.0)
  1. HAE hereditary angioedema
  2. aAll HAE-specific medications recorded during study period